📅 PUBMED DAILY TRIAGE — 2026-05-17 (Sunday)

Window: 2026-05-16T09:00Z → 2026-05-17T09:00Z (CRDT) Topics scanned: 10 (9 watchlist + 1 sentinel) | Articles reviewed: ~22 raw | Candidates evaluated: 17 classified High priority: 4 | Standard: 13 | Low/archive: 4 (count-only) | Unsolicited finds: 2 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection / Hematologic Malignancies

TR-2026-05-17-001 / PMID 42141842 · Long-Term Effect of H. pylori Eradication on Gastric Atrophy and Intestinal Metaplasia After Endoscopic Resection of Gastric Neoplasm · 9/10 · 🔴 EARLY_CANCER_DETECTION H. pylori eradication produces nearly 6-fold improvement in gastric atrophy (OR 5.81) and 3-fold in intestinal metaplasia (OR 3.23) vs persistent infection over median 5.9 years in a validated RCT follow-up from Korea's NCC — the strongest confirmation yet that the Correa carcinogenesis pathway is reversible at scale. (Kim YI et al., Helicobacter 2026)

Rare Diseases / Novel Therapeutics

TR-2026-05-17-002 / PMID 42141895 · DOREMY Trial: Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma (Phase 2) · 8/10 · 🟠 NOVEL_TREATMENT Long-term follow-up (median 66mo, n=90, 9 centers EU+US) of dose-reduced preoperative RT (36Gy vs standard 50Gy) in myxoid liposarcoma achieves 5-year LRFS 97.4%, OS 88.5%, with favorable toxicity — authors explicitly recommend clinical adoption via shared decision-making for this rare cancer. (Lansu J et al., JAMA Oncology 2026)

Cardiovascular-Metabolic

TR-2026-05-17-003 / PMID 42141868 · Influenza Vaccination Attenuates AMI and Stroke Risk Following Influenza Infection: Nationwide Danish SCCS Study · 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE Nationwide Danish self-controlled case series (n=1,221, 2014-2025): influenza infection increases 7-day AMI risk 4.7x and stroke 2.9x; seasonal vaccination substantially attenuates this excess cardiovascular risk (interaction p=0.020) — strong real-world evidence for cardiovascular-framed flu vaccination messaging. (Croci R et al., Euro Surveillance 2026)

Aging / Population Health

TR-2026-05-17-004 / PMID 42141891 · Clinical and Economic Benefits of Seasonal COVID-19 Vaccination in Germany: ROUTINE-COV19 Study · 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE Propensity-matched cohort of 146,132 Germans shows 57% reduction in long COVID (RR 0.43), 59% fewer COVID hospitalizations, 25% lower all-cause mortality with seasonal COVID vaccination in the endemic phase — population-scale validation for continued immunization recommendations. (Schmetz A et al., Euro Surveillance 2026; BioNTech/Pfizer co-authored — flag COI for Phase 2)

🟢⚪ STANDARD (5-7) — Top by Topic

Hematologic Malignancies (best: 42141842 above)

• TR-2026-05-17-005 / PMID 42141736 · Marked Variation in rDLBCL Trial Eligibility Limits Real-World Applicability · 7/10 · Policy · 52% of real-world DLBCL patients ineligible for any of 7 registrational trials; eligibility 4-22%; survival equivalent to ineligible patients (Goodall E et al., Br J Haematol 2026)
• TR-2026-05-17-016 / PMID 42141851 · H. pylori in Hematologic Disorders: Mechanistic Review · 5/10 · Review · Comprehensive synthesis of H. pylori → IDA, ITP, MALT lymphoma mechanisms and eradication outcomes (Fathalizade K et al., Helicobacter 2026)
• TR-2026-05-17-017 / PMID 42141705 · Psychological Distress + Peripheral Monocytes in CLL/SLL Active Surveillance · 5/10 · Preliminary · Stress/anxiety → lower intermediate monocytes in n=76 CLL/SLL patients; novel psychoneuroimmunology signal (Cancer Med 2026)

Novel Therapeutics

• TR-2026-05-17-006 / PMID 42141789 · ICI Induction+Consolidation vs Consolidation-Only in Stage III NSCLC · 7/10 · PSM retrospective, n=265, 2y PFS equivalent (56.8 vs 62.2%) — consolidation-only supported (Oncoimmunology 2026)
• TR-2026-05-17-011 / PMID 42141753 · Neoadjuvant Immunochemotherapy in Pulmonary Lymphoepithelioma Carcinoma · 6/10 · Rare cancer (PLEC), n=40, pCR 20%, 2y EFS 76.6%, comparable to LUSC/LUAD (Cancer Med 2026)
• TR-2026-05-17-012 / PMID 42141507 · HCC Treatment Patterns in Japan: LRT+Systemic Therapy Real-World Database · 6/10 · n=15,285; systemic therapy pre-LRT in <13% despite evidence (Cancer Med 2026)

Cardiovascular-Metabolic

• TR-2026-05-17-009 / PMID 42141839 · Prehospital BP + ICH Outcomes: Time-Dependent Association · 7/10 · Retrospective registry n=690; high prehospital BP predicts mortality only in ≥3h arrivals; time-contextualized prehospital BP guidance (Eur J Neurol 2026)

Aging / Population Health

• TR-2026-05-17-013 / PMID 42141740 · Medication Safety Strategies for Geriatric ED Patients: Narrative Review · 6/10 · Reconciliation + CDSS + pharmacist integration for ~10% medication-related older adult ED visits (Acad Emerg Med 2026)
• TR-2026-05-17-015 / PMID 42141880 · Waning Humoral Immunity After Mpox Infection/Vaccination, Canada · 6/10 · IgG declines post-infection; MVA-BN vaccination doesn't extend longevity; 30-month vaccinees near-seronegative (Euro Surveill 2026) [unsolicited]

Precision Oncology

• TR-2026-05-17-010 / PMID 42141746 · Molecular Tumor Boards in Melanoma: 78% Actionable but 66% Not Implemented · 6/10 · n=80, bicenter Germany; when implemented: PFS 7.85 vs 4.34mo; late referral major barrier (Int J Cancer 2026)

Rare Diseases

• TR-2026-05-17-008 / PMID 42141852 · DRESS ICU Predictors: Hospital-Acquired DRESS + Severity (aOR 5.2/12.5) · 7/10 · Multicenter n=207, 39 Paris-area hospitals; 17% ICU; ICU mortality 20% (JEADV 2026)

Sentinel (Unsolicited)

• TR-2026-05-17-007 / PMID 42141850 · Vonoprazan Dual Therapy vs BQT for H. pylori: 4-Arm RCT · 7/10 · n=400; VA (83%), VM (82%) equivalent to BQT (83%) with fewer AEs; simplified H. pylori regimen (Helicobacter 2026) [unsolicited]

💡 UNSOLICITED FINDS

📊 TODAY'S BREAKDOWN

By research category:

• Prevention: 4 (42141842, 42141868, 42141891, 42141854)
• Treatment Innovation: 6 (42141895, 42141736, 42141789, 42141753, 42141507, 42141851)
• Diagnostics: 4 (42141839, 42141740, 42141705, 42141746)
• Public Health: 2 (42141880, 42141507 secondary)
• Genomics/Precision Medicine: 1 (42141746)

By evidence maturity:

• Validated: 11
• Exploratory: 3
• Potentially Practice-Changing: 1 (42141895 DOREMY)
• Not classified/LOW: 2

By watchlist topic (reviewed / kept / highest score):

• Hematologic malignancies: 3 reviewed / 4 kept (incl. cross-topic) / 9 (42141842)
• CBC-based diagnostics/ML: 0 / 0 / N/A
• Early cancer detection: 0 direct / 1 indirect / 9 (42141842)
• AI/ML diagnostics: 0 / 0 / N/A
• Precision oncology: 2 / 2 / 6 (42141746)
• Novel therapeutics: 4 / 4 / 8 (42141895)
• Cardiovascular-metabolic: 0 direct / 2 via sentinel / 8 (42141868)
• Aging/longevity: 4 / 3 / 8 (42141891)
• Rare diseases: 0 direct / 2 via sentinel / 8 (42141895)
• Sentinel: 10 / 8 evaluated / 8

By source type: peer_reviewed 17 | preprint 0

Topics with ZERO 8+ articles from direct queries: CBC-based diagnostics/ML, AI/ML diagnostics, Early cancer detection (direct), Cardiovascular (direct GLP-1/SGLT2), Rare diseases (direct) → HIGH articles for cardiovascular and rare diseases came exclusively via sentinel scan

🔧 RUN NOTES

• Sunday indexing: 5 of 9 direct watchlist searches returned 0 results in 24h CRDT window. Expected for Sunday. No window expansion triggered (total >5 relevant records found).
• H. pylori theme issue: 4 articles from Helicobacter Vol 31 Issue 3 (May-Jun 2026) indexed simultaneously — review (42141851), RCT follow-up (42141842), Iran guidelines (42141854), and vonoprazan RCT (42141850).
• Early cancer detection streak: Direct liquid biopsy/ctDNA/MCED searches continue to return 0 results (3rd+ consecutive). Recommend broader query (e.g., "cancer screening" OR "early detection" without requiring liquid biopsy terms) or 48h window expansion on next weekend run. Best available find today (42141842, score 9/10) came via hematologic malignancies query — EARLY_CANCER_DETECTION streak now BROKEN.
• Rolling 7-day: Topics producing zero 8+ articles: CBC/ML diagnostics (consecutive), AI/ML diagnostics (consecutive). These may need query review.
• Sentinel performance: Delivered 2 HIGH and 4 STANDARD articles (42141895, 42141868 HIGH; 42141852, 42141839, 42141850, 42141880 STANDARD). Sentinel highly productive today given sparse targeted queries.
• COI note: ROUTINE-COV19 study (42141891) co-authored by BioNTech/Pfizer employees. Phase 2 pipeline should apply independent evidence grading weight.
• Animal study discarded: PMID 42141809 (orthotopic CRC organoid model, Oncoimmunology) scored 4/10 — excluded from output per LOW threshold.
• Candida biofilm paper (42141906): Surfaced in sentinel via "mortality"/"survival" keyword; biologically irrelevant to watchlist — discarded.